![Theresa M. LaVallee](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Theresa M. LaVallee
Director Técnico/Científico/I+D en
COHERUS ONCOLOGY, INC.
.
Perfil
Theresa M.
LaVallee is currently Chief Scientific & Development Officer at Coherus Oncology, Inc. since 2021.
Former positions include Senior Director-Cell Biology at CASI Pharmaceuticals, Inc., Senior Director-Translational Medicine at MedImmune LLC from 2008 to 2013, Vice President-Translational Medicine at Kolltan Pharmaceuticals, Inc. from 2013 to 2014, Senior VP-Regulatory & Precision Medicine at Celldex Therapeutics, Inc. from 2016 to 2017, and VP-Translational Medicine & Regulatory Affairs at The Parker Institute For Cancer Immunotherapy from 2017 to 2021.
Education includes a doctorate from the University of California, Los Angeles and an undergraduate degree from the University of California, Santa Barbara.
Cargos activos de Theresa M. LaVallee
| Empresas | Cargo | Inicio |
|---|---|---|
| COHERUS ONCOLOGY, INC. | Director Técnico/Científico/I+D | 17/12/2021 |
Antiguos cargos conocidos de Theresa M. LaVallee.
| Empresas | Cargo | Fin |
|---|---|---|
The Parker Institute For Cancer Immunotherapy
 The Parker Institute For Cancer Immunotherapy Miscellaneous Commercial ServicesCommercial Services Operates cancer research | Consejero General | 01/12/2021 |
| CELLDEX THERAPEUTICS, INC. | Consejero General | 01/06/2017 |
MedImmune LLC
 MedImmune LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Corporate Officer/Principal | 01/04/2013 |
CASI Pharmaceuticals, Inc. /Old/
 CASI Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Develops pharmaceutical drugs for treating cancer and inflammatory diseases | Corporate Officer/Principal | - |
Kolltan Pharmaceuticals, Inc.
 Kolltan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures monoclonal antibody drugs | Corporate Officer/Principal | - |
Formación de Theresa M. LaVallee.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
74
Relaciones de 1er grado
8
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 8 |
|---|---|
MedImmune LLC
MedImmune LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
CASI Pharmaceuticals, Inc. /Old/
CASI Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Develops pharmaceutical drugs for treating cancer and inflammatory diseases | Health Technology |
Kolltan Pharmaceuticals, Inc.
Kolltan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures monoclonal antibody drugs | Health Technology |
University of California, Los Angeles
 University of California, Los Angeles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Santa Barbara
 University of California, Santa Barbara Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Celldex Therapeutics, Inc.
 Celldex Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes immunotherapy technologies for the treatment of cancer and other diseases | Health Technology |
Coherus BioSciences, Inc.
 Coherus BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a commercial-stage biopharmaceutical company that engages in research, development and commercialization of immunotherapies to treat cancer | Health Technology |
The Parker Institute For Cancer Immunotherapy
The Parker Institute For Cancer Immunotherapy Miscellaneous Commercial ServicesCommercial Services Operates cancer research | Commercial Services |
- Bolsa de valores
- Insiders
- Theresa M. LaVallee
